Dr Geoffrey Cumming – BAppSc, BSc(Hons), MBA, PhD, MAICD
Non Executive Director– Chairman of the Remuneration and Nomination Committee.
– Member of the Audit and Risk Committee.
– Member of Clinical Advisory Board.
Dr Cumming has over 20 years’ experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems – Oceania Regional Centre, where he transformed a lossmaking business to one achieving over 30% compound annual growth over a four-year period and the highest profitability levels in Roche’s global organisation. He was also Managing Director and CEO of Biosceptre Ltd, an Australian‑based biotechnology company commercialising a range of products in cancer diagnosis and treatment.
During his tenure he was responsible for taking research from Sydney University through to product registration.
This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. Dr Cumming is currently Chairman of Inoviq Ltd (ASX:IIQ).
Mr Christopher Parker – BAppSc (QUT) and Grad Dip – Marketing (UTS)
Non Executive Director– Member of the Audit and Risk Committee.
– Member of the Remuneration and Nomination Committee.
– Chair of the Clinical Advisory Board.
Mr Parker has over 30 years of experience in both domestic and international life sciences companies
predominately through a career with Roche Diagnostics (“Roche”), an internationally renowned pharmaceutical and diagnostics company. In his final role with Roche, before retiring in the second half of 2017, he was Managing Director for UK & Ireland and Management Centre European Agents where he had responsibility for all diagnostic products in the Roche portfolio and an annual budget of £250 million. Prior to this he held various roles in general management, marketing and business development in Canada, Asia and Australia targeting the centralised pathology laboratory, decentralised point-of-care (POC), molecular diagnostics and applied sciences research markets.
Dr Katherine Woodthorpe AO – BSc (Hons), PhD, FAICD, FTSE
Non Executive Director– Member of the Audit and Risk Committee.
– Member of the Energy Advisory Board.
– Member of the Remuneration and Nomination Committee.
Dr Woodthorpe AO is an experienced Chair and Non-Executive Director serving for over 20 years on the boards of a variety of organisations including listed entities, government boards and for-purpose organisations. She has a strong track record in a broad range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. She has been cited in various media as one of Australia’s most influential people in innovation. She has sat on the boards of a number of healthcare companies including Ventracor and Sirtex Ltd. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Prior to AVCAL, she held a broad range of management and board positions, in Australia and overseas. Katherine commenced her career as a chemist then moved to sales of specialised laboratory equipment into the medical and oil, gas and petrochemical sectors covering the geographies of Europe, Asia and the Middle East before locating permanently to Australia in 1988.
Katherine holds a Bachelor of Science (Manchester Uni.) and Ph.D. (Chemistry, Leicester Uni, UK). Katherine is the Chair of the “Vision 2040” committee of the Commonwealth government, developing the strategy for medical research investment over the next couple of decades.
Katherine is a Fellow of the Australian Institute of Company Directors.
Ms Glenda McLoughlin – BEcon, MBA, FAICD
Non Executive Director– Chair of the Audit and Risk Committee.
– Member of the Remuneration and Nomination Committee.
– Chair of the Energy Advisory Board.
Ms McLoughlin is an experienced Chair and Non-Executive Director with over 25 years’ experience as an
Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Glenda co-founded listed Australian gas company Metgasco Ltd (ASX:MEL), where she was Executive Director and Chief Financial Officer for eight years.
Glenda served as a non-executive director of the National Art School from 2014 to 2019 and is currently Chair of SCECGS Redlands.
Mr Ewen Crouch AM – BEc (Hons), LLB, FAICD
Chairman– Member of the Remuneration and Nomination Committee.
– Member of the Audit and Risk Committee.
Mr Crouch is currently Chairman of Corporate Travel Management Limited (ASX:CTD) and a non-executive director of BlueScope Steel Limited (ASX:BSL). He also serves on the board of Jawun.
Ewen was a Partner at Allens from 1998 to 2013 where his roles included Chairman of Partners, Co-Head Mergers and Acquisitions and Equity Capital Markets, Executive Partner – Asian Offices and Deputy Managing Partner, as well as 11 years’ service on its board. He served as a director of Mission Australia between 1995 and 2016, including 7 years as its Chairman.
Mr Crouch served as a non-executive director of Westpac Banking Corporation from 2013 to 2019. He was a member of the Takeovers Panel from 2010 to 2015, a member of the Commonwealth Remuneration Tribunal from 2015 to 2019 and a director of the Sydney Symphony Orchestra from 2009‑2020.
Ewen is a Fellow of the Australian Institute of Company Directors.
Mr David Radford – BSc(Hons), MBA(Exec), GAICD
CEO & Managing Director– Member of the Audit and Risk Committee.
– Member of the Remuneration and Nomination Committee.
– Member of the Energy Advisory Board.
– Member of Clinical Advisory Board.
Mr Radford is an internationally experienced CEO and Company Director with a track record of identifying and delivering profitable growth across a range of industries and geographies. He has direct experience in coordinating international teams, executing business turnarounds, product development and product launches, and operational initiatives to drive material growth in revenue and profits.
Most recently, he served as CEO of Australian medical device company AllVascular, which develops and sells patented drug delivery technology with regulatory approval in Europe (CE Mark) and Australia (TGA).
David has built his career through senior executive roles at blue-chip listed companies, ASX-listed small caps and private equity-owned businesses including Recall Asia (then part of Brambles Australia), General Electric and Nanosonics Limited (ASX:NAN). With experience across public capital markets, private companies and working directly with private equity investors, Mr Radford has a wealth of experience managing and communicating with multiple stakeholders.
David holds an MBA from the Australian Graduate School of Management, a Bachelor of Science (Biological Sciences) from Bristol Polytechnic and is a Graduate of the Australian Institute of Company Directors.